Class action lawsuit against GlaxoSmithKline (NASDAQ: GSK) was initiated by injured patients who had experienced severe gastrointestinal (GI) tract complications after taking OTC drugs (i.e., drugs that do not contain medicinal ingredients). These drugs, among others, are commonly known as “non-steroidal anti-inflammatory” drugs (NSAIDs), including ibuprofen (Tylenol), naproxen (Naprosyn, Aleve), ibuprofen (Advil, Motrin), indomethacin (Relia), indocetine (Aceform), ketoprofen (Orudis), trazodone (Tenex), zonisamide (Zantac) and diclofenac (Diclofen), which are commonly used to treat GI symptoms. According to the class action lawsuit, Omeprazole (Aceform) is one of these non-steroidal anti-inflammatory drugs (NSAIDs) that caused long-term stomach ulcers and liver damage. The manufacturer, GlaxoSmithKline, is also responsible for these injuries and has hence failed to provide proper warnings and adequate clinical trials to the affected parties. The said drugs are manufactured in various sizes and concentrations. A class action lawsuit was filed on behalf of the patients seeking compensation for their damages.
Class Action Lawsuit Against Omeprazole
As a consumer, you can protect yourself from dangerous pharmaceuticals by following these tips. First, know what your options are when it comes to brands and concentration levels of these potent medications. Second, do some research on which among the various brands of Omeprazole (Aceform) that have been recently released are the widest choice available in the market. Third, ask your doctor if the recommended dose of Omeprazole (Aceform) for you is effective enough to minimize the risks of side effects and complications that can arise from taking this potent anti-inflammatory drug.
Some generic versions of Omeprazole (Aceform) are also available in the market.
However, these medicines do not have the same properties as those of the original brand. One example of an equivalent generic drug is Isotretinoin, which is marketed under the trade name Metabolism Plus. Isotretinoin is another strong anti-inflammatory medication that act similarly to Omeprazole (Aceform) but has weaker properties and fewer side effects. You can search for other generic versions of the medicines mentioned in this article at healthcare websites.
The second class action lawsuit against Omeprazole (Aceform) is maintained by the National Institute of Arthritis and Musculoskeletal Disease (NIAMS).
According to the studies, Aceform had been found to increase cholesterol levels (a possible cause of atherosclerosis) by more than 40% in people with obesity. It is the only ingredient contained in Aceform that has proven a consistent elevation of LDL (low density lipoprotein) cholesterol levels. As for the HDL cholesterol, there was no significant change noted in patients taking either placebo or the equivalent generic drug, which suggests that a favorable effect of Aceform on high cholesterol levels is not being detected.
The third class action lawsuit against Omeprazole (Aceform) states that one of its major ingredients, icorpirithine, can cause sudden death in patients who ingest it.
This is despite the fact that icorpirithine does not actually exist in nature. The ingredient is believed to act as a teratogen (a chemical that causes birth defects) by interacting with the human cyst cells (which form the basis of the lungs and heart). The cysts that form in the lungs can be very dangerous if they block the airways or become malignant.
The fourth class action lawsuit against Omeprazole (Aceform) claims that the drug causes kidney failure in dogs. The dogs had to be euthanized because of their inability to metabolize icorpirithine. The manufacturer has denied these allegations. The FDA has not determined the validity of the claims.
The fifth class action lawsuit against Omeprazole (Aceform) involves liver problems.
The dogs that were fed icorpirithine developed portal hypertension, a condition that could lead to liver failure. The dogs died from this condition. The manufacturer has acknowledged liability in the case.
It is difficult to predict whether Omeprazole will be found to cause serious adverse side effects in humans. No long term animal studies have been done on the subject. One indication that these drugs may cause problems in people is that studies in Europe found that icorpirithine increased the risk of depression. If further studies confirm this link between these medicines and depression, then the FDA should consider lowering the concentration of icorpirithine in dietary supplements.